eTheRNA extends leadership team with the appointment of Dr. Volker Germaschewski as Senior Vice President for R&D
Dr. Volker will be responsible for leading, prioritizing and expanding eTheRNA research and development programmes and the development and prioritization of R&D strategies in all therapeutic areas.
eTheRNA immunotherapies NV (‘eTheRNA’ or ‘The Company’), a clinical-stage company developing immunotherapies from its proprietary mRNA TriMix platform for the treatment of cancer and infectious diseases, announced today that Dr. Volker Germaschewski has been appointed Senior Vice President for R&D. Volker joins eTheRNA from Kymab Ltd. (Cambridge, UK) where, over 10 years, he was initially Senior Director Discovery and subsequently Vice President of Haematology. Prior to that he held several positions in Biopharm R&D at GlaxoSmithKline.
“I am excited to join eTheRNA at this incredible time of unprecedented advances in mRNA technologies within vaccine and therapeutics development”, said Dr. Germaschewski. “I am looking forward to working with the team at eTheRNA and our partners and our collaborators as we accelerate development of our promising and innovative oncology and infectious disease technologies and products.”
About eTheRNA Immunotherapies
eTheRNA immunotherapies is a clinical-stage company developing innovative immunotherapies from its proprietary mRNA and formulation platforms. eTheRNA was established in January 2013 as a spin-off from the VUB university in Belgium and is developing products for the treatment of cancer and infectious disease.